Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND) (HASD_PIB_IND)

NCT04579120 RECRUITING

To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).

Details

Lead sponsor	Tammie L. S. Benzinger, MD, PhD
Status	RECRUITING
Enrolment	650
Start date	2021-09-01
Completion	2025-12

Conditions

• Alzheimer Disease

Interventions

• [11C]-Pittsburgh Compound B ([11C]PiB)
• F 18 AV-1451 (Flortaucipir)

Primary outcomes

• AD Biomarkers seen on Amyloid PET at Baseline and Years 1, 2, and/or 3 — 5 years
  This Project aims to identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD). This will be done by comparing imaging biomarkers seen with amyloid PET and the tracer C-11 PIB at baseline to imaging biomarkers collected longitudinally, at years 1, 2, and/or 3.
• AD Biomarkers seen on Tau PET at Baseline and Years 1, 2, and/or 3 — 5 years
  This Project aims to identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD). This will be done by comparing imaging biomarkers seen with tau PET and the tracer Flortaucipir at baseline to imaging biomarkers collected longitudinally, at years 1, 2, and/or 3.
• AD Biomarkers seen on MRI at Baseline and Years 1, 2, and/or 3 — 5 years
  This Project aims to identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD). This will be done by comparing imaging biomarkers seen with MRI at baseline to imaging biomarkers collected longitudinally, at years 1, 2, and/or 3.
• Compare and Correlate Predictive Ability of Biomarkers Seen with Different Imaging Variables for Onset of Symptoms — 5 years
  This project aims to compare and correlate the predictive ability of baseline values and rates of change of molecular biomarkers of AD for onset of AD symptoms with other variables. Variables obtained in this project include: 1) volumetric MRI, 2) MRI measures of vascular burden, 3) functional MRI, 4) amyloid PET, and 5) tau PET.

Countries

United States